HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Researc... (or basic research toxicity safety and ri...)

HOME >> BIOLOGY >> TECHNOLOGY

HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services

Date:12/3/2008

or basic research, toxicity, safety and risk assessment for the biopharmaceutical and environmental arenas, and quality control and potency assays for stem cell transplantation processing laboratories. HemoGenix(R) produces and sells its assays directly or through its distributors worldwide. HemoGenix(R) is a privately owned company.

About ORF Genetics, hf.

ORF Genetics was the first company to introduce biorisk-free growth factors to global R&D. Headquartered in Reykjavik, Iceland, ORF Genetics, hf. is a privately owned biotech company that is committed to economically viable, green technology for the production of growth factors and hard to produce recombinant proteins. Utilizing its unique Orfeus(TM) plant-based expression system, the company is currently the only provider of such growth factors to serve the needs of the medical research, cell culture media, diagnostics and cosmetic markets. ORF was recently awarded the prestigious 2008 Icelandic Innovation Award by the Icelandic Center for Research and the Icelandic Trade Council. The annual award is given to a single Icelandic company that is pioneering research and development.

    CONTACT:
    Ivan N. Rich, PhD
    Founder and CEO
    719-264-6250
    ivannr@hemogenix.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

0

GOOD

Page: 1 2 3
Related biology technology :

1. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
2. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
3. Enigma Diagnostics Announces the Opening of a United States Office
4. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
5. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
6. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
7. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
10. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
11. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease

Post Your Comments:

HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Researc...(or basic research toxicity safety and ri...)